Zhi Tong Cai Jing·2025-10-17 11:20Group 1 - Fosun Pharma announced that its subsidiary, Fosun Kerry, signed a capital increase agreement with Shenzhen Biomedical Industry Fund for a total investment of 600 million yuan, aimed at supporting the operational and business development of Fosun Kerry [1] - The investment will be made in phases, with the new registered capital not exceeding 524.44 million yuan [1] - A co-investment agreement was also signed with 14 participants, including current directors and core management, who will contribute a total of 3.525 million yuan to the new registered capital of 3.081 million yuan [1] Group 2 - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party investors plan to contribute a total of 1.246664 million yuan to the new registered capital of 1.089664 million yuan [2] - An incentive plan was approved to attract and retain key talents, allowing for the issuance of equity rights worth up to 93.22 million yuan, with the first batch not exceeding 76.18 million yuan [2] Group 3 - The first batch of incentive rights includes several directors and senior management, also constituting a related party transaction [3] - If all incentive rights are fully vested, these related party investors could indirectly hold 12.76 million yuan of registered capital through a total investment of 9.694159 million yuan [3]